Regeneron Pharmaceuticals and Sanofi-Aventis entered into research collaboration to discover, develop and commercialize human therapeutic antibodies utilizing Regeneron’s proprietary VelociSuite technologies including VelocImmune®. The deal would worth up to US$1.222 B to Regeneron if specific milestones and sales targets are met.